Clinical studies and trials on traditional medicine and natural products
-
Upload
prof-dr-basavaraj-nanjwade -
Category
Health & Medicine
-
view
31 -
download
1
Transcript of Clinical studies and trials on traditional medicine and natural products
20th World Congress on Clinical Nutrition, Bangakok, Thailand
1
Clinical Studies and Trials on Traditional Medicine and
Natural Products
Prof. Dr. Basavaraj K. NanjwadeDepartment of Pharmaceutics
Rani Chennamma College of Pharmacy,Belagavi-590010, Karnataka, INDIA.
E-mail: [email protected]
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
2
The Ultimate Goal
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
315/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
4
Discovery, Design and Development
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
5
Medicines research
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
6
Clinical Pharmacokinetics• Clinical pharmacokinetics is the process of applying
pharmacokinetic principles to determine the dosage regimens of specific drug products for specific patients to maximize pharmacotherapeutic effects and minimize toxic effects.
• TDM stands for therapeutic drug mointoring
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
7
Clinical Pharmacokinetics
• Application of these principles requires an understanding of the absorption, distribution, metabolism, and excretion characteristics of specific drug products in specific diseases and patient populations
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
8
Pharmacokinetics
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
9
Clinical Studies
• Treatment studies1. Randomized controlled trial
– Blind trial– Non-blind trial
2. Adaptive clinical trial3. Nonrandomized trial (quasi-experiment)
– Interrupted time series design (measures on a sample or a series of samples from the same population are obtained several times before and after a manipulated event or a naturally occurring event) - considered a type of quasi-experiment
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
10
Clinical Studies
• Observational studies1. Cohort study
– Prospective cohort– Retrospective cohort– Time series study
2. Case-control study– Nested case-control study
3. Cross-sectional study– Community survey (a type of cross-sectional study)
4. Ecological study
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
11
Clinical Drug Development
• Bioavailability• Bioequivalence• Cross-over designs• Comparison• Dose-ranging• Special populations (renal, hepatics, elderly)• Drug-drug interactions• Drug interaction• Drug metabolism• Safety and efficacy• Patient selections
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
12
Steps in Pharmaceutical Products
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
13
Phase I Clinical Trial(INITIAL SAFETY TESTING IN A SMALL GROUP OF HEALTHY VOLUNTEERS )
• In Phase I trials the candidate drug is tested in people for the first time. • These studies are usually conducted with a small number of healthy
volunteers, generally 100 or less. • The main goal of a Phase I trial is to assess the safety of the medicine
when used in humans. • Researchers look at the pharmacokinetics of a drug: How is it absorbed? • How is it metabolized and eliminated from the body? • They also study the drug’s pharmacodynamics: Does it cause side
effects? • These closely monitored trials are designed to help researchers
determine what the safe dosing range is and if the candidate medicine should move on to the next stage of development.
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
14
Phase I• Patients: 20 to 100 healthy volunteers or people with
the disease/condition.
• Length of Study: Several months
• Purpose: Safety and dosage • Percentage of Drugs that Move to the next Phase
70%
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
15
Study Types Included• Safety & Tolerability studies (Single/ multiple dose in
patients or healthy volunteers)
• Oncology studies in patients with tolerability / MTD as primary endpoint (efficacy might be a secondary endpoint)
• Drug-Drug interaction & Food Effect
• PK in renal or hepatic impaired patients
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
16
Phase II Clinical Trial(ASSESS SAFETY AND EFFICACY IN A SMALL GROUP OF PATIENTS)
• In Phase II trials researchers evaluate the candidate drug’s effectiveness in 100 to 500 patient volunteers with the disease or condition under study.
• Researchers also analyze optimal dose strength and schedules for using the drug and examine the possible short-term side effects (adverse events) and risks associated with the drug.
• If the drug continues to show promise, they prepare for the much larger Phase III trials.
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
17
Phase II• Phase IIA: Exploratory (non-pivotal) study that has
clinical efficacy, Pharmacodynamics or biological activity as primary endpoint, conducted in patients or healthy volunteers.
• Phase IIB: Definite dose range finding study in patients with efficacy as primary endpoint.
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
18
Phase II• Patients: Up to several hundred people with the
disease/condition.
• Length of Study: Several months to 2 years
• Purpose: Efficacy and side effects • Percentage of Drugs that Move to the Next Phase
33%
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
19
Study Type Included• Proof of concept, efficacy, or mechanism
• Mechanistic studies
• Dose range exploration
• Pilot studies
• Definite dose finding studies
• Extension studies of Phase IIB studies
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
20
Phase III Clinical Trial(DEMONSTRATE SAFETY AND EFFICACY IN A LARGE GROUP OF PATIENTS)
• Phase III trials generate statistically significant data about the safety, efficacy and the overall benefit-risk relationship of the investigational medicine.
• Phase III trials may enroll 1,000 to 5,000 patients or more across numerous clinical trials sites around the world.
• This phase of research is essential in determining whether the drug is safe and effective.
• It also provides the basis for labeling instructions to help ensure proper use of the drug (e.g., information on potential interactions with other medicines, specific dosing instructions, etc.)
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
21
Phase III• Patients: 100 to 5000 volunteers who have the disease
or condition
• Length of Study: 1 to 4 years
• Purpose: Efficacy and monitoring of adverse reactions
• Percentage of Drugs that Move to the Next Phase 25-30%
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
22
Phase III• Phase IIIA: A Pivotal study that is a trial designed &
executed to get statistically significant evidence of efficacy and safety as required NDA/ sNDA approval. It also provides the basis for labeling instructions to help ensure proper use of the drug (e.g., information on potential interactions with other medicines, specific dosing instructions, etc.)
• Phase IIIB: A study started prior to approval and whose primary intention is support of publications rather than registration or label changes. The results are not intended to be included in the submission dossier.
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
23
Study Time Included
• Pivotal studies (vs placebo/comparator)• Long term safety studies for registration• Local registration studies• Post marketing study commitments• Phase IIIA extension studies• Studies intended to support publication, claims or
to prepare launch, which start before approval but are not intended for Regulatory submissions
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
24
Phase IV
• Phase IV: A study started after approval with primary intention to support publications rather than registration or label changes.
• The results are not intended to be included in a submission dossier.
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
25
Phase IV Clinical Trial
• Patients: Several thousand volunteers who have the disease/condition
• Purpose: Safety and efficacy
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
2615/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
2715/12/2016
Patient care
Knowledge of drug therapy
Knowledge of the disease
Knowledge of laboratory
and diagnostic skills
Communication skillsPatient
monitoring skills
Physical assessment
skills
Drug Information
Skills
Therapeutic planning
skills
Knowledge of nondrug
therapy
20th World Congress on Clinical Nutrition, Bangakok, Thailand
28
Reference• Namrata Bahadur, Overview of Drug Development, Head of Clinical
Development & Medical Affairs Emerging Growth Markets, 17th - 21st March, Bangkok.
• http://www.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf• http://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm• http://www.camargopharma.com/clinical-studies phases-i-iv.aspx• http://www.cailsilorin.com/safety-and-efficacy/• http://www.yourgenome.org/facts/how-are-drugs-designed-and-developed
.• http://cenblog.org/the-haystack/2012/02/drug_design/• Anurag S Rathore & Helen Winkle Quality by design for
biopharmaceuticals. Nature Biotechnology 27, 26 - 34 (2009), doi:10.1038/nbt0109-26.
15/12/2016
20th World Congress on Clinical Nutrition, Bangakok, Thailand
29
THANK YOU14/12/206
E-mail: [email protected]/12/2016